"uuid:ID","id","studyAcronym","studyVersion","studyRationale","studyTitle"
"fc912f36-06fa-4629-aa82-77faf14e2a01","StudyVersion_1","H2Q-MC-LZZT","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease"
